Back to Search
Start Over
Investigating the clinical potential for 14-3-3 zeta protein to serve as a biomarker for epithelial ovarian cancer.
- Source :
-
Journal of ovarian research [J Ovarian Res] 2013 Nov 15; Vol. 6 (1), pp. 79. Date of Electronic Publication: 2013 Nov 15. - Publication Year :
- 2013
-
Abstract
- Objective: Recently, 14-3-3 zeta protein was identified as a potential serum biomarker of epithelial ovarian cancer (EOC). The goal of this study was to investigate the clinical potential of 14-3-3 zeta protein for monitoring EOC progression compared with CA-125 and HE4.<br />Design: Prospective follow-up study.<br />Setting: University of Pecs Medical Center Department of Obstetrics and Gynecology/Oncology (Pecs, Hungary).<br />Population: Thirteen EOC patients with advanced stage (FIGO IIb-IIIc) epithelial ovarian cancer that underwent radical surgery and received six consecutive cycles of first line chemotherapy (paclitaxel, carboplatin) in 21-day intervals.<br />Methods: Pre- and post-chemotherapy computed tomography (CT) scans were performed. Serum levels of CA-125, HE4, and 14-3-3 zeta protein were detected by enzyme-linked immunosorbent assay (ELISA) and quantitative electrochemiluminescence assay (ECLIA).<br />Main Outcome Measures: Serum levels of CA-125, HE4, and 14-3-3 zeta protein, as well as lesion size according to pre- and post-chemotherapy CT scans.<br />Results: Serum levels of CA-125 and HE4 were found to significantly decrease following chemotherapy, and this was consistent with the decrease in lesion size detected post-chemotherapy. In contrast, 14-3-3 zeta protein levels did not significantly differ in healthy postmenopausal patients versus EOC patients.<br />Conclusions: Determination of CA-125 and HE4 serum levels for the determination of the risk of ovarian malignancy algorithm (ROMA) represents a useful tool for the prediction of chemotherapy efficacy for EOC patients. However, levels of 14-3-3 zeta protein were not found to vary significantly as a consequence of treatment. Therefore we question if 14-3-3 zeta protein is a reliable biomarker, which correlates with the clinical behavior of EOC.
Details
- Language :
- English
- ISSN :
- 1757-2215
- Volume :
- 6
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of ovarian research
- Publication Type :
- Academic Journal
- Accession number :
- 24238270
- Full Text :
- https://doi.org/10.1186/1757-2215-6-79